A phase 2, double-blind, randomized, placebo-controlled study to assess the efficacy and safety of tx000045 after 24 weeks of treatment in patients with pulmonary hypertension secondary to heart failure with preserved ejection fraction (PH-HFpEF)

• Código protocolo: TX000045-003
• Código EudraCT: _
• Grupo de investigación: Enfermedades Cardiovasculares
• Servicio: Cardiología
• Investigador/a principal:  Rodenas Alesina, Eduard
• Patología: Malalties del sistema circulatori
• Fase: Fase II